🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#specialissues #submissionswelcome 💡#Robot-Assisted #Urologic #Cancer Surgery: Current Challenges and Future Perspectives 🔗mdpi.com/journal/medici… 🧑‍🔬Guest Editor: Dr. Francesco Claps Dr. Roberto Contieri Deadline: 30 June 2025

📢 Very happy to share our multicentric study on 140 #RCC patients who received #radicalnephrectomy at 3 Italian Institutions 📍32.9% with #CONUTscore > 2 📌37% with renal function drop at 24 months Just published👇 mdpi.com/3002192 #mdpicancers via Cancers MDPI

Combination BCG + IO Trials as Frontline Tx: Phase 3 Trials of PD-1/ PD-L1 Inhibitors in BCG Naïve HR-NMIBC Cheryl Lee #SCSAUA24 UroToday.com South Central Section of the AUA

To predict whether treatment with checkpoint inhibitors will work, you need to take the tumor environment into consideration, PhD Candidate Alberto Gil Jimenez proposes. Antoni van Leeuwenhoek TU Delft He will defend his thesis on November 19 ➡️ bit.ly/4fmHv3j

Wonderful inaugural meeting between the Global Society of Rare GU Tumors and IBCG discussing how to advance the field of rare bladder cancer variants Philippe spiess Ashish M. Kamat, MD, MBBS

📹 How can artificial intelligence improve our understanding of tumour complexity? Dr. Benjamin Pradere interviews Dr. Markus Eckstein on how AI is speeding up the process of diagnosis. But what next? And what about AI for #bladdercancer pathology? 👇 bladder.uroonco.uroweb.org/video/how-ai-c…

Erdafitinib is just around the corner for #metastatic #urothelialcancer! However, FGFR3 alterations are rare (10-15%) in MUC! In our recently published study in Nature Communications we thus asked whether we could use #AI to prescreen histopathology slides for presence of FGFR3

The REBACARE trial ➡️ pre Neph U intravesical MMC instillation ❌ did not reduce 2-year intravesical recurrence (IVR) (24% vs 26%). However, those w pre surgical URS had a ⬆️5x higher risk of IVR compared to those without (12% vs 60%) 🚨Judicious use of d-URS is crucial in

Ever thought anterior prostate cancers have high PSAs and biopsies show lower grade disease? Now our definitive paper by Sammy Isabella Gharbieh on how to diagnose & treat APC rdcu.be/d7Psw Ata Jaffer Dan Chia. Joshua Mullin

Our editorial on the #BladderPath study: Could MRI-first staging streamline MIBC treatment? Skipping TURBT may reduce delays—especially for those needing palliative care or radiotherapy. Journal of Clinical Oncology Andrea Necchi jim catto Nick James also on @Prof-Nick-James.bsky.social #OncSurgery #BladderCancer

Honored to join the EAU YAU Urothelial Carcinoma as an Associate Member! Very grateful to Marco Moschini and Giorgio I. Russo 🩺 for this unique opportunity and to all my mentors that supported me in these years 🙏🏻 Looking forward to collaborating with this incredible team 🚀

Mistakes happen! 🔄 After correcting the results, we found: 📌 1817 lesions – 1529 MRI – 1325 patients 📍 Mapped Transperineal Biopsies 🔹 MRI-: 8% CsPCa 🔸 PIRADS 3: 25% CsPCa 🔺 PIRADS 4-5: 68% CsPCa link.springer.com/article/10.100…

Proud to stand alongside this incredible group of innovators and leaders in urology. The future of our field is in great hands. #Urology #EAU2025

NMIBC trial timelines: <2020 to 2028+ Unbelievable disease space at the moment! Trinity J. Bivalacqua UroToday.com #EAU25

DOMANI 10 e 11 aprile a Castelfranco Veneto 📆 🩺 Advanced Uro-Oncology Days - 3° Edizione Due giornate dedicate all’evoluzione delle terapie nelle neoplasie urologiche, con focus su approcci multidisciplinari, integrazione di nuove molecole e applicazione pratica delle più

Great talks and state of the art lectures here in Palermo about novel evidence among all Uro-Oncology fields. Glad to discuss clinical case scenario in MIBC on TMT vs. radical cystectomy. Congrats to Nicola Pavan and all the Scientific Committee for this excellent meeting 🚀

NEW: The EAU Guidelines Bot The right answers, seconds away Ask personalised treatment questions and receive instant answers based on the EAU Guidelines. Available in each topic section of the EAU Guidelines. Try it today via the Guidelines page: uroweb.org/guidelines

A 🧵 on our recent study on surveillance for IR-NMIBC European Urology Oncology authors.elsevier.com/c/1l7pU_wtP00L… There is limited evidence on follow-up for IR-NMIBC. We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.

Excellent comprehensive review + metaanalysis on the diagnostic role of #PSMA Pet in #ProstateCancer ✅ High diagnostic value of PSMA PET, especially when combined with #MRI ✅ NPV indicates limitations to guide LND - not enough to omit biopsy European Urology OncoDaily Elio Mazzone

Our team is in Sevilla for #UROonco25 📩 #NMIBC Deintensify LG Biomarkers to ⬇️ cystoscopy in HG #MIBC ctDNA is the future #UTUC Tailored patient care Go for kidney-sparing treatment European Association of Urology (EAU) EAU Edu Platform UROONCO EAU Young Academics